Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
162.90B
Market cap162.90B
Price-Earnings ratio
38.43
Price-Earnings ratio38.43
Dividend yield
5.93%
Dividend yield5.93%
Average volume
34.33M
Average volume34.33M
High today
$29.21
High today$29.21
Low today
$28.49
Low today$28.49
Open price
$29.10
Open price$29.10
Volume
5.32M
Volume5.32M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.58
52 Week low$23.58

Stock Snapshot

The current Pfizer(PFE) stock price is $28.58, with a market capitalization of 162.9B. The stock trades at a price-to-earnings (P/E) ratio of 38.43 and offers a dividend yield of 5.93%.

On 2026-09-03, Pfizer(PFE) stock traded between a low of $28.49 and a high of $29.21. Shares are currently priced at $28.58, which is +0.3% above the low and -2.2% below the high.

The Pfizer(PFE)'s current trading volume is 5.32M, compared to an average daily volume of 34.33M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.21 and a 52-week low of $23.58.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.21 and a 52-week low of $23.58.

PFE News

TipRanks 1h
Notable open interest changes for September 3rd

Wednesday’s total option volume of 62.0 million contracts resulted in net open interest growth of 5.97 million calls and 4.36 million puts. NVIDIA (NVDA), Broad...

TipRanks 1h
Medicus Pharma Secures Global Pfizer License for CD228V

Medicus Pharma Ltd ( (MDCX) ) just unveiled an update. On September 2, 2026, Medicus Pharma Ltd., via Medicus Pharma Inc., entered a co-development and license...

24/7 Wall St. 12h
Pfizer Reaches $29.02, a New 52-Week High Investors Should Note - 247wallst.com

...

Pfizer Reaches $29.02, a New 52-Week High Investors Should Note - 247wallst.com

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

Nasdaq 21h
Should You Buy Pfizer Stock Below $30?

Key Points Pfizer's financial results aren't great, and the company will face important patent cliffs relatively soon. However, the company may have a deep en...

Should You Buy Pfizer Stock Below $30?
TipRanks 21h
Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1 STUDY TO EVALUATE SAFETY,...

Simply Wall St 1d
Pfizer Following FDA Vaccine Approval Has Fair Value Back In Focus

Advertisement Why the new COVID-19 vaccine approval matters for Pfizer stock Pfizer (PFE) and BioNTech just received FDA approval for their 2026 to 2027 COMIR...

Pfizer Following FDA Vaccine Approval Has Fair Value Back In Focus
24/7 Wall St. 2d
CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here's Why Rivian's Didn't.

Investing CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here’s Why Rivian’s Didn’t. Three blue-chip CFO swaps touched off double-digit stock ra...

CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here's Why Rivian's Didn't.
Simply Wall St 3d
Did Targeted XFG COVID Shots Just Recenter Pfizer's Post‑Pandemic Investment Narrative?

Pfizer and BioNTech previously received FDA approval for their 2026–2027 COMIRNATY XFG mRNA COVID-19 vaccine, tailored to the XFG variant, for adults 65+ and hi...

Did Targeted XFG COVID Shots Just Recenter Pfizer's Post‑Pandemic Investment Narrative?
24/7 Wall St. 3d
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't

Investing Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t Pfizer and Starbucks both raised their outlooks this summer, but a louder recover...

Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't
TipRanks 5d
Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer is quietly reshaping its pipeline, unveiling...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.